Cited by 138Liver physiology and pathologyLiver Disease Diagnosis and TreatmentDrug-Induced Hepatotoxicity and Protection

Effect of pirfenidone on rat hepatic stellate cell proliferation and collagen production

Di Sario, Antonio, Bendia, Emanuele, Svegliati Baroni, Gianluca, Ridolfi, Francesco, Casini, Alessandro, Ceni, Elisabetta, Saccomanno, Stefania, Marzioni, Marco +4 more·2002·Journal of Hepatology

Abstract

Background/aims Pirfenidone has been recently shown to reduce dimethynitrosamine-induced liver fibrosis in the rat, but no information are available on the effect of this drug on cultured hepatic stellate cells (HSC). Methods HSC proliferation was evaluated by measuring bromodeoxyuridine incorporation; PDGF-receptor autophosphorylation, extracellular signal-regulated kinase (ERK1/2) and pp70(S6K) activation were evaluated by western blot; protein kinase C activation was evaluated by western blot and by ELISA; type I collagen accumulation and alpha1(I) procollagen mRNA expression were evaluated by ELISA and northern blot, respectively. Results Pirfenidone significantly inhibited PDGF-induced HSC proliferation, starting at a concentration of 1 microM, with a maximal effect at 1000 microM, without affecting HSC viability and without inducing apoptosis. The inhibition of PDGF-induced HSC proliferation was associated neither with variations in PDGF-receptor autophosphorylation, or with ERK1/2 and pp70(S6K) activation. On the other hand, pirfenidone was able to inhibit PDGF-induced activation of the Na(+)/H(+) exchanger, which is involved in PDGF-induced HSC proliferation in HSC, with a maximal effect at 1000 microM and inhibited PDGF-induced protein kinase C activation. Pirfenidone 100 and 1000 microM inhibited type I collagen accumulation in the culture medium induced by transforming growth factor(beta1) by 54% and 92%, respectively, as well as TGF(beta1)-induced alpha1(I) procollagen mRNA expression. Results Pirfenidone could be a new candidate for antifibrotic therapy in chronic liver diseases.

Integrity signals

Registry

Crossref · 10.1016/s0168-8278(02)00245-3

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Pirfenidone's main anti-fibrotic efficacy in the liver is mostly attributed to suppression of HSC activation.

    “but its main anti-fibrotic efficacy in the liver is mostly attributed to suppression of HSC activation (138, 139).”

    From Targeting macrophages in liver fibrosis (2026) · cites this paper as [138]

Cited by

Sorted by citations

Authors
Di Sario, A., Bendia, E., Svegliati Baroni, G., Ridolfi, F., Casini, A., Ceni, E., Saccomanno, S., Marzioni, M., Trozzi, L., Sterpetti, P., Taffetani, S., & Benedetti, A.
Affiliations
University of Florence (IT)
Venue
Journal of Hepatology
Publisher
Elsevier BV
Published
2002-11
Volume
37
Issue
5
Pages
584-591
ISSN
0168-8278 (ISSN-L)
OpenAlex
W2029181407
Cited by
138
References
0
Citations by year
2026: 2 · 2025: 7 · 2024: 2 · 2023: 7 · 2022: 4 · 2021: 6 · 2020: 7 · 2019: 6 · 2018: 8 · 2017: 5 · 2016: 6 · 2015: 6 · 2014: 9 · 2013: 11 · 2012: 6
FWCI
2.58
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Hepatology (publishedVersion)
  • PubMed (publishedVersion)
  • Florence Research (University of Florence) (submittedVersion)
  • Università Politecnica delle Marche (Università Politecnica delle Marche) (submittedVersion)
Topics
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
  • Health Sciences › Medicine › Epidemiology › Liver Disease Diagnosis and Treatment
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
Keywords
pirfenidone, hepatic stellate cells, stellate cell proliferation, collagen synthesis, liver fibrosis, antifibrotic therapy, PDGF receptor, Na+/H+ exchanger, protein kinase C, ERK1/2, TGF-β1, chronic liver disease
MeSH terms
Animals, Antineoplastic Agents, Cell Division, Cells, Cultured, Culture Media, Male, Phosphorylation, Platelet-Derived Growth Factor, Protein Kinase C, Pyridones, RNA, Messenger, Gene Expression, Transforming Growth Factor beta, Rats, Sprague-Dawley, Apoptosis, Sodium-Hydrogen Exchangers, Mitogen-Activated Protein Kinase 1, Receptor, Platelet-Derived Growth Factor beta, Mitogen-Activated Protein Kinases, Hepatocytes, Collagen Type I, Ribosomal Protein S6 Kinases, 70-kDa, Mitogen-Activated Protein Kinase 3, Rats, Transforming Growth Factor beta1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review